From Financial Modeling Prep: 2024-12-27 12:49:00

Raymond James analysts raise Masimo’s price target to $194 from $170, maintaining an Outperform rating. The shift back to healthcare is expected to drive sustainable growth, with EPS potentially growing at 15% annually. Margin expansion initiatives and a new board aim to enhance profitability, positioning Masimo for long-term value and operational efficiency.



Read more at Financial Modeling Prep:: Masimo’s Target Raised to $194 as Core Healthcare …